Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
F-box only protein 10 (FBXO10) is a member of the F-box protein family, characterized by the presence of an approximately 40-amino acid F-box motif that enables interaction with the SCF (SKP1-CUL1-F-box protein) E3 ubiquitin ligase complex[1][5]. FBXO10 acts as a substrate-recognition component within SCF complexes, mediating the ubiquitination and degradation of specific protein targets. Notably, FBXO10 targets the antiapoptotic protein BCL2 for ubiquitination, thereby promoting its degradation and playing an important role in apoptosis regulation[1][5]. FBXO10 also participates in the ubiquitination and subsequent degradation of RAGE (receptor for advanced glycation end products) and the regulation of BCR signaling via degradation of HGAL/GCSAM[1]. Dysregulation of FBXO10 has been associated with lymphoid malignancies, particularly large B-cell lymphoma[1]. The broader FBX protein family, including FBXO10, is involved in critical cellular processes such as protein turnover, cell cycle regulation, and response to cellular stress[2]. While no drugs are currently known to specifically target FBXO10, its role in disease suggests potential future as a therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on F-box only protein 10 (FBXO10).